Today Illumina; tomorrow the world? Where the acquisition might really take Roche
This article was originally published in Scrip
Executive Summary
Hoffmann-La Roche wants to acquire the San Diego-based gene sequencing and array diagnostic company leader Illumina and the fact that it is willing to engage in a hostile takeover of the company and start the bidding in that process at a 64% premium to Illumina's most recent stock price indicated that the Swiss giant is really serious.